Jul 12, 2023
WuXi STA Launches Another Parenteral Formulation Manufacturing Line
Credit: Comezora/Getty Images WuXi STA, a subsidiary of WuXi AppTec, reports
Credit: Comezora/Getty Images
WuXi STA, a subsidiary of WuXi AppTec, reports that a new parenteral formulation manufacturing line has started operation at the drug product site in Wuxi city, China. It is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of ten million units.
The new line features a fully automatic vial loading/unloading system and a built-in 15 m2 lyophilizer in a fully enclosed isolator. The filling line supports vials in a full range of sizes for solutions and lyophilized powder while allowing rapid switches between modes for maximum filling flexibility and efficiency. The filling speed can reach 200 vials per minute. The facility is designed per global cGMP standards, according to WuXi officials, and equipped with state-of-the-art containment system and advanced filling machine. From vial cleaning, drying, filling to freeze-drying, the entire process is automated in the isolator.
Located in Jiangsu, China, the WuXi city site is an integrated drug product R&D and manufacturing campus with an analytical platform for both oral and injectable formulations. The site has passed Pre-Approval Inspections from both European Medicines Agency (EMA) and China National Medical Products Administration (NMPA).
The injectable platform at the site supports all synthetic modalities including small molecules, oligonucleotides, peptides, and complex conjugates.
With the sterile lipid nanoparticle (LNP) facility at Wuxi city, the site is well positioned to provide formulation development and manufacturing for oligonucleotides and the conjugates, says Minzhang Chen, PhD, co-CEO of WuXi AppTec and CEO of WuXi STA.
"To continue enhancing the injectable platform capabilities, a high potency (HP) parenteral formulation manufacturing line is slated to begin operations in Q3 2023 at WuXi city site," he adds. "In addition, injectable formulation development and manufacturing services will be available from the company's new site at Middletown Delaware in the U.S. in 2025, further enhancing the platform capability and capacity for global customers."
Log in to leave a comment